All In MedTech

Device Trial Radar · NCT03150030

Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Nov 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Feb 1, 2017

Primary completion

Jan 6, 2020

Study completion Jan 6, 2020

Sponsor

Lead sponsor
University Hospital, Gentofte, CopenhagenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 11, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Twenty-one patients with insulin-treated type 2 diabetes with diabetic complications will be recruited to Part 1 of the study, a three-hour combined hyper- and hypoglycaemic clamp, along with a control group of twenty-one individuals with normal glucose tolerance matched for age, gender, and body mass index. Patients with type 2 diabetes will be scheduled for a three-week run-in period with LR and CGM prior to participation in Part 1. Only patients with a well-functioning loop-recorder and who can comply with CGM will be included. Patients with type 2 diabetes will continue in part 2 of the study, a one year observational study employing CGM and LR and clinical examination after 1, 3, 6, 9, and 12 months and an extended observation period of 2 years employing LR and clinical examination.

Conditions

  • Diabetes Mellitus, Type 2
  • Arrhythmia, Cardiac

Interventions

  • Combined hyper- and hypoglycaemic clampOther

    During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.

  • Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)Device

    Implantation of a loop-recorder

  • Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)Device

    Monitoring with a continuous glucose monitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Clinically relevant arrhythmiasTime frame: 0-240 min during the combined hyper- and hypoglycaemic clamp
  2. Part 2: Prevalence of clinically relevant arrhythmias as defined aboveTime frame: Within 12 months
  3. Part 2: Clinically relevant arrhythmias during hypoglycaemia compared to euglycaemiaTime frame: Within 12 months

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gentofte Hospital

    Hellerup, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.